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Abstract
Non-alcoholic fatty liver disease (NAFLD) is the 
most common chronic liver disease worldwide. Its 
pathogenesis is complex and not yet fully understood. 
Over the years many studies have proposed various 
pathophysiological hypotheses, among which the 
currently most widely accepted is the “multiple 
parallel hits” theory. According to this model, lipid 
accumulation in the hepatocytes and insulin resistance 
increase the vulnerability of the liver to many factors 
that act in a coordinated and cooperative manner to 
promote hepatic injury, inflammation and fibrosis. 
Among these factors, adipose tissue dysfunction and 
subsequent chronic low grade inflammation play a 
crucial role. Recent studies have shown that vitamin 
D exerts an immune-regulating action on adipose 
tissue, and the growing wealth of epidemiological data 
is demonstrating that hypovitaminosis D is associated 
with both obesity and NAFLD. Furthermore, given the 
strong association between these conditions, current 
findings suggest that vitamin D may be involved in the 
relationship between adipose tissue dysfunction and 
NAFLD. The purpose of this review is to provide an 
overview of recent advances in the pathogenesis of 
NAFLD in relation to adipose tissue dysfunction, and in 
the pathophysiology linking vitamin D deficiency with 
NAFLD and adiposity, together with an overview of the 
evidence available on the clinical utility of vitamin D 
supplementation in cases of NAFLD.
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Core tip: Obesity-associated chronic low-grade in-
flammation plays a pivotal role in the development of 
non-alcoholic fatty liver disease (NAFLD). Vitamin D 
deficiency is associated with both obesity and NAFLD, 
and its anti-inflammatory and immune-modulatory 
properties provided plausible mechanisms by which 
hypovitaminosis D may link adipose tissue dysfunction 
and NAFLD. Animal studies showed beneficial effect of 
vitamin D supplementation on systemic inflammation 
and NAFLD, but these data are not confirmed by the 
results of clinical trials so far conducted in humans.
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INTRODUCTION
Definition  and  epidemiology  of  non-­alcoholic  fatty  liver  
disease
Non-alcoholic fatty liver disease (NAFLD) is a condition 
characterized by the accumulation of excessive fat 
in the liver in individuals with no history of alcohol 
abuse (< 30 g/d in men and < 20 g/d in women) and 
no competing etiologies for hepatic steatosis. NAFLD 
represents a spectrum of diseases ranging from simple 
steatosis to nonalcoholic steatohepatitis (NASH), 
which  may  evolve  into  hepatic  fibrosis,  cirrhosis,  and  
eventually hepatic carcinoma[1-5]. 
NAFLD is a global public health problem[6]: it is 
currently the most common chronic liver disease 
worldwide, affecting approximately 20%-35% of 
adults in the general population[7]. Furthermore, the 
number of patients affected is growing rapidly, and the 
disease has now reached epidemic proportions. The 
reported prevalence of NAFLD is 20%-30% in western 
countries and approximately 15% in Asian countries. 
In individuals who are of normal weight and who have 
no metabolic risk factors, the prevalence of NAFLD 
is about 16%. Though, it rises dramatically in high-
risk individuals such as patients with diabetes (60%), 
hyperlipidemia (90%) and obese patients (91%)[8-12]. 
In addition to diabetes and obesity, other independent 
risk factors identified for the disease to progress 
toward  NASH  and  to  develop  fibrosis  and  cirrhosis are 
age, female sex, Hispanic ethnicity, smoking[13,14].
Notably, 55% of patients with NAFLD have normal 
aminotransferase levels[15], suggesting that studies using 
liver enzymes as a surrogate for NAFLD significantly 
underestimate the prevalence of this condition. NAFLD 
diagnosis is usually made by ultrasonography, which 
enables moderate and severe steatosis to be detected 
with acceptable sensitivity but only once the level of fat 
accumulated in the liver exceeds 33%. More sensitive 
techniques, including nuclear magnetic resonance 
imaging and spectroscopy, are hindered by the high 
costs involved and the lack of feasibility in large 
populations. The American Association for the Study of 
Liver Diseases sets the limit for the diagnosis of NAFLD 
at a biopsy-proven hepatic fat content greater than 
5%[7]. Liver biopsy is therefore still considered to be the 
gold standard, although its widespread use is restricted 
by a number of factors, including the cost and lack of 
feasibility in population-based studies on both ethical 
and practical grounds. 
The clinical implications of the alarming prevalence 
of NAFLD, our limited knowledge of its underlying 
pathophysiologic mechanisms, and the difficulties in 
both its diagnosis and treatment explain why NAFLD is 
currently  a  field  of  such  intensive research.
Pathogenesis  of  NAFLD
A histological grading and staging system for non-alcoholic 
steatohepatitis was proposed by Brunt et al[16] in 1999. 
The amount of fat, fibrosis and necro-inflammation 
were the parameters included in the Brunt’s criteria for 
grading and staging NASH. The presence of hepatic 
steatosis and inflammation with hepatocyte injury 
(ballooning)  defined  the  diagnosis  of  NASH,  according  
to recently recommended guideline of the American 
Association for the Study of Liver Disease[7].
In patients with NAFLD, studies have shown that 
the vast majority of hepatic fat (59%) originates 
from adipose tissue lipolysis, 26% comes from de 
novo lipogenesis and 15% originates from the diet[17]. 
Hepatic steatosis results when the balance between 
delivery and synthesis of free fatty acids exceeds the 
liver capacity to oxidize or export them. Accumulation 
of lipids can exert toxic effects on the liver by 
inefficient oxidation or by activation of inflammatory 
pathways. Further, increased lipid metabolites such as 
diacylglycerol and ceramides may themselves cause 
cell injury and insulin resistance (IR) by interfering 
with the ability of insulin to phosphorylate insulin 
receptor substrate-2 through activation of protein 
kinase C-epsilon [18-21].
In 1998, Day et al[22] presented the “two hits” 
hypothesis to describe the pathogenesis of NAFLD. 
They  proposed  that  the  “first  hit”  was  represented  by  
lipid accumulation in the hepatocytes and consequent 
IR, and that the “second hit” was represented by 
increased oxidative stress that resulted in hepatic 
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inflammation, fibrosis and necrosis. This model is 
now considered obsolete, because it is inadequate to 
explain the several molecular and metabolic changes 
which lead to the development of NAFLD. 
According to the current “multiple-hits” theory, 
the “first hit” sensitizes the liver to further insults, 
which are represented by a variable combination of 
different hits, such as oxidative stress and subsequent 
lipid peroxidation, mitochondrial dysfunction, gut 
microbiota, adipose tissue dysfunction, and adipokine 
secretion, all of which are ultimately capable of 
inducing hepatic injury[23-26].
In this context, novel data has unraveled the role 
of adipose tissue dysfunction as a central player in 
the ectopic fat distribution associated with obesity 
and dysmetabolic conditions. In this review, we are 
therefore  focusing  on  recent  findings  that  provide  an  
insight into the role of adipose tissue dysfunction in the 
pathogenesis of NAFLD.
ADIPOSE TISSUE DYSFUNCTION AND 
NAFLD
Obesity is a major risk factor for the development 
of NAFLD, but not all patients with obesity go on to 
develop NAFLD. In the National Health and Nutrition 
Examination Survey III, 7.4% of lean adults and 
27.8% of overweight/obese adults had hepatic 
steatosis which could be detected by ultrasound[27]. 
One reason for this incomplete overlap between 
obesity and NAFLD is related to the use of Body Mass 
Index  (BMI)  to  define  obesity,  meaning  that,  although  
BMI  cut-­off  points  have  good  specificity  for  detecting  
excess adiposity, they lack sensitivity[28] and also fail 
to provide information about the distribution, type and 
quality of body fat. 
Traditionally, adipose tissue was regarded as an 
inert organ for the storage of energy, but in the last 
few years this conventional view has been radically 
altered. Currently, adipose tissue is considered to be 
the major, and possibly the largest, endocrine organ, 
having the ability to synthesize and release a variety 
of hormones, cytokines, both complement and growth 
factors, extracellular matrix proteins and vasoactive 
agents, collectively known as adipokines. Therefore, 
it has been shown that adipose tissue biology is much 
more complex than previously considered[29] and 
visceral adipose tissue (VAT) dysfunction has been 
proposed as a major contributor to NAFLD[30,31]. 
VAT consists of a loose connective tissue that 
is predominately populated with tightly packed 
adipocytes that are vascularized by a dense 
network of capillaries. A second component of VAT 
is represented by the stromal vascular fraction and 
includes pre-adipocytes, multi-potent stem cells, 
fibroblasts, vascular endothelial cells, and immune 
cells surrounded by the extracellular matrix (ECM). 
The ECM contains a variety of structural proteins and 
collagen networks that anchor adipocytes to maintain 
the structural and functional integrity of the tissue[32].
In obese subjects, excessive nutrient intake and the 
consequent accumulation of triglycerides result in an 
expansion of VAT that causes adipocytes hypertrophy 
and alters the stromal vascular compartment[33,34]. 
Progressive adipocytes hypertrophy is associated with 
increased adipokine and pro-inflammatory cytokine 
production[35] and leads to hypoxia and adipocyte cell 
death[36,37]. Dysfunctional VAT also undergoes excessive 
fibrosis  by  enhancing  the  expression  of  different  ECM  
components such as collagen VI[32,38,39]; progressive 
fibrosis  may  also  limit  the  amount  of  fat  stored  in  the  
adipocytes, thus promoting the deposition of ectopic 
fat in liver and muscle[40]. 
One hallmark of adipose tissue dysfunction is the 
accumulation of inflammatory cells in the context 
of VAT; in particular, active macrophages infiltrate 
VAT[41,42] and surround dead adipocytes in typical 
“crown-like structures”[43] (Figure 1).
Two major subtypes of macrophage are found in 
adipose tissue: “alternatively activated” M2 macrophages 
and “classically activated” M1 macrophages, and 
the proportions of these cell populations in VAT are 
dependent on the tissue microenvironment. M2 
macrophages maintain VAT homeostasis in lean 
individuals through the secretion of anti-inflammatory 
cytokines, such as IL-10, whereas in obese individuals, 
pro-­M1  polarized  macrophages  secrete  pro-­inflammatory  
cytokines, including TNF, IL-1 and IL-6, which can 
promote  the  proliferation  of  other  inflammatory  immune  
cells,  chronic  local  and  systemic  inflammation,  and  can  
directly alter insulin receptor signaling in adipocytes, 
leading to IR[44,45]. The mechanisms leading to increased 
infiltration of macrophages into VAT are not entirely 
clear; however, it is known that in obese individuals 
adipocytes increase their expression of monocyte 
chemoattractant protein 1 (MCP-1) in order to recruit 
macrophages[46].
Moreover, adipose tissue secretes a large number 
of adipokines. These are delivered directly to the liver 
via its portal vein, and then exert local and peripheral 
effects. It is increasingly recognized that an impaired 
pattern of adipokines secretion could play a pivotal role 
in the development of NAFLD[47].
Adipokines  and  NAFLD
Several investigators have attempted to demonstrate 
a role for adipokines in the pathogenesis of NAFLD 
and in the progression to NASH, although the data 
on many of the adipokines apparently involved are 
sometimes controversial. Adipokines are characterized 
by complex interactions and the role they may exert 
in the pathogenesis of NAFLD is often difficult to 
interpret[48]. Those adipokines whose effects on the 
liver are defined and supported by solid data are 
adiponectin, leptin, TNF- and IL-6.
TNF- is the most commonly investigated and 
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phosphorylation in activated hepatic stellate cells[79]. 
Certain in vivo studies have shown that low 
serum levels of adiponectin are associated with 
NAFLD[75,76,80-85] and that low adiponectin was an 
independent risk factor for NAFLD[86]; furthermore, 
that adiponectin is a good predictor of necro-
inflammation  and  fibrosis  in  animal  and  in vitro models 
of NAFLD[78,87-89]. Moreover, studies in humans have 
shown reduction of adiponectin in the serum, as well 
as reduction of the expression of its receptor in the 
liver of patients with NASH when compared to BMI-
matched patients with steatosis[54,83,90], providing 
robust evidence that decreased adipocyte production of 
adiponectin plays an important role in the progression 
of NAFLD. 
The identification of serum adipokines associated 
with liver histology and, more specifically, with the 
severity  of  steatosis,  fibrosis  and  inflammation  might  
provide useful information about NAFLD pathogenesis 
and form the basis for new diagnostic and therapeutic 
approaches. 
VITAMIN D, ADIPOSITY AND NAFLD
There is growing evidence to indicate that in addition 
to maintaining calcium and phosphorus homoeostasis 
and bone health[91], vitamin D also displays pleiotropic 
actions on several tissues, organs and metabolic 
processes[92-96].  Vitamin  D  deficiency  is  currently  a  global  
health issue and may contribute to the pathogenesis of 
many disorders, such as obesity, metabolic syndrome 
and type 2 diabetes[97-99]. 
Despite several epidemiological studies showing the 
existence of a close relationship between obesity and 
hypovitaminosis D[100-105], the mechanisms underlying 
characterized. It is secreted by AT-associated macro-
phages  as  a  response  to  chronic  inflammatory  activity.  
Human and experimental studies have suggested that 
TNF- plays a role in all of the phases of fatty liver 
disease, from simple steatosis to steatohepatitis and 
cirrhosis; TNF- also enhances IR[49-51] and promotes 
the development of IR complications in vitro[52,53]. 
Human studies have revealed that a high TNF- level 
increases the risk of developing NAFLD in healthy 
individuals[49] and predicts the progression and severity 
of NASH[49,54-60].
In the pathogenesis and progression of IR and 
NAFLD, IL-6 exerts a role extensively investigated 
in both experimental models of steatosis and liver 
injury, and in humans. In vitro studies have shown 
that IL-6 promotes IR via several mechanisms[61-63], 
and in animal models this effect was evident in the 
liver[64-66]. Serum IL-6 levels were increased in subjects 
with biopsy-proven NAFLD compared to controls[67], 
and these levels correlated with the degree of 
inflammation,  the  stage  of  the  fibrosis  and  with  IR
[68]. 
Leptin plays a role in both the development and 
progression of NAFLD, contributing to IR, steatosis 
and,  through  a  pro-­inflammatory  role  in  the  regulation  
of  hepatic  stellate  cells,  to  hepatic  fibrosis
[69]. In NASH 
patients leptin levels were found to be increased and 
to be related to the grade of hepatic steatosis[70-72].
Adiponectin is produced specifically by differenti-
ated adipocytes[73] and is an anti-inflammatory and 
insulin-sensitizing hormone[74]. It has been largely 
demonstrated that adiponectin prevents hepatocytes 
lipid accumulation by enhancing -oxydation and 
by reducing synthesis of free fat acids[75-77], that it 
mediates  anti-­inflammatory  activity  by  lowering  NFB 
action[78], and antagonizes leptin-induced STAT3 
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Figure 1  Normal visceral adipose tissue consists of a loose connective tissue that is populated with tightly packed adipocytes. In lean individuals VAT 
homeostasis  is  maintained  by  adiponectin  released  by  adipocytes  and  by  M2  macrophages  through  the  secretion  of  anti-­inflammatory  cytokines,  such  as  interleukin  
(IL)-­10  and  arginase-­1.  During  obesity,  dysfunctional  visceral  adipose   tissue  (VAT)  undergoes  excessive  fibrosis  and  accumulation  of   inflammatory  cells.  Active  
macrophages  surround  dying  adipocytes  (DA)  in  typical  “crown-­like  structures”.  Pro-­M1  polarized  macrophages  secrete  pro-­inflammatory  cytokines  including  TNF,  
IL-1  and  IL-­6,  which  can  promote  chronic  local  and  systemic  inflammation.  VAT  secretes  a  large  number  of  adipokines  which  could  play  a  pivotal  role  in  development  
of  NAFLD.  NAFLD:  Non-­alcoholic  fatty  liver  disease.
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this association are largely unknown. Interestingly, 
many studies have suggested that adipose tissue 
could be a direct target of vitamin D, and that this 
molecule might have a role in modulating adipose 
tissue pathophysiology[106-116].
Notwithstanding the inverse association between 
BMI and fat mass[114], higher plasma 25OHD has 
been associated with lower amounts of VAT and with 
reduced omental adipocyte size[115-119], suggesting a 
link between vitamin D status and fat distribution. This 
is further substantiated by reports of the regulatory 
effects of vitamin D on adipose tissue and lipid storage 
and by the fact that vitamin D receptor (VDR) is 
expressed in adipocytes both in animals models and 
in humans. In particular, the expression of VDR gene 
has been reported in cultured adipocytes[110], in human 
pre-adipocytes[111] and human subcutaneous and 
visceral adipose tissue[112,113]. 
Interestingly, it has been suggested that vitamin 
D may provide a protective effect in obese individuals 
who  have  healthy  metabolic  profiles  as  characterized  
by the absence of IR-related conditions and low 
systemic  inflammation  despite  an  increased  body  fat  
mass[120-122].  
Thus, these data suggest an involvement of vitamin 
D in the regulation of adipose tissue inflammation. 
The  transduction  of  inflammatory  pathways  in  adipose  
tissue involves the activation of nuclear factor - (NF-
B) that regulates the transcription of a wide range 
of inflammatory mediators. Several in vitro studies 
showed that vitamin D exerts an anti-inflammatory 
action on both mouse and human adipocytes by 
decreasing chemokines and cytokines expression via 
the involvement of p38 MAP kinase and the NF-B 
classical inflammatory pathway[123-125]. Very recently, 
Karkeni et al[126] demonstrated that vitamin D modulates 
the expression of miRNAs in adipocytes in vitro and 
in adipose tissue in vivo through the NF-B signaling 
pathway, representing, thus, a new mechanism of 
regulation  of  adipose  tissue  inflammation  by  vitamin  D.
In line with these data, vitamin D supplementation 
has been recently demonstrate to decrease circulating 
pro-inflammatory adipokines, in particular IL-6 and 
TNF-, in diet-induced obese mice[127,128]. Moreover, 
in a large cohort of human patients, serum 25OHD 
concentration correlated with low leptin[129] and high 
adiponectin levels, irrespective of their BMI[130].
The role of vitamin D in the pathogenesis of NAFLD 
is an active area of research[131]. The existence of an 
independent association between hypovitaminosis D 
and NAFLD has been largely demonstrated in studies 
conducted using liver imaging[132-136] and biopsy[137,138]. 
In particular, low vitamin D levels were associated with 
the histological severity of NAFLD/NASH[137-143] and 
with the prevalence of NAFLD among individuals with 
normal liver enzymes[131]. Overall, in the only meta-
analysis available in the literature, a 26% additional 
risk of vitamin D deficiency has been reported in 
subjects with NAFLD compared to controls subjects[139]. 
Experimental studies have shown that vitamin D 
also  directly  exerts  anti-­inflammatory,  anti-­proliferative  
and  anti-­fibrotic  activities  in  the  liver
[144,145] by linking 
VDR, widely expressed throughout the liver, in 
hepatocytes, cholangiocytes, and lymphocytes[146-148]. 
There is extensive evidence to show that the VDR 
function in the liver regulates not only the hepatic 
lipid  metabolism  but  also  hepatic  necro-­inflammation  
and  fibrosis;;  notably,  in  chronic  hepatic  diseases  VDR  
expression  negatively  correlates  with  the  inflammatory  
damage[149]. 
In vitro and in vivo preclinical studies have found 
that vitamin D decreased hepatic stellate cell activation, 
suggesting it may have a potential role to protect 
against  hepatic  fibrosis
[150,151].
Data from animal studies further support the notion 
that vitamin D plays an immunomodulatory role in 
NAFLD. Roth et al[152] showed that a lack of vitamin D 
intake in obese rats led to the progression of NAFLD 
with increased lobular inflammation and a higher 
NAFLD activity score as evaluated by liver histology; 
at the same time, mRNA levels of resistin, IL-6 and 
TNF-, were increased in the liver. All the above 
markers are involved in oxidative stress and hepatic 
inflammation. Therefore, in another study on NASH 
rat, phototherapy, by increasing the serum active form 
of vitamin D, reduced hepatocyte inflammation and 
fibrosis, improved insulin resistance, and increased 
serum adiponectin, while at the same time reducing 
the hepatic expression of inflammatory genes TNF- 
and TFG-[153]. 
It has also been demonstrated that a vitamin 
D-deficient high-fat diet hampers the enterohepatic 
circulation of bile acids, leading to NASH[154]. Further-
more, a recent study evidenced that long-term dietary 
vitamin D depletion could generate spontaneous liver 
fibrosis  in  a  mice  model
[155]. Han et al[156] demonstrated 
that vitamin D supplementation in mice with NASH 
reduced the hepatic levels of cytokeratin 18 apoptotic 
fragment M30, a widely validated marker of hepatic 
damage[157].
These observations regarding the link between 
vitamin D serum levels and the development and 
progression of NAFLD suggest that vitamin D supple-
mentation might represent a new therapeutic option in 
the management of NAFLD. Nevertheless, controversies 
exist due to the limited number of studies and the 
conflicting results of prospective randomized clinical 
trials in humans designed to examine the role of vitamin 
D supplementation in NAFLD. 
Our group has recently published the results of 
a randomized, double-blind, placebo-controlled trial 
involving 55 patients with type 2 diabetes and MRI-
diagnosed NAFLD. In our study, the participants 
underwent a 24-wk course of high-dose oral vitamin 
D supplementation and no effect was shown on either 
the hepatic fat content or on markers of hepatic injury, 
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i.e., serum transaminases, CK-18 and PIIINP[158]. 
Lorvand Amiri et al[159] conducted a randomized 
placebo-controlled double-blind clinical trial to evaluate 
the potential beneficial effects of oral calcium plus 
calcitriol supplementation versus calcitriol alone on liver 
enzymes and ultrasound-measured fat liver content in 
120 patients with NAFLD, showing decreased improved 
serum ALT in the calcium plus calcitriol treated group.
Previously, a prospective small pilot study evaluated 
the impact of a 24-wk course of high-dose oral vitamin 
D supplementation on the liver histology of 12 non-
cirrhotic  NASH  patients.  The  study  found  no  beneficial  
effects of this treatment on hepatic damage or insulin 
sensitivity[160]. 
Sharifi  et al[161] also investigated the effect of oral 
vitamin D supplementation in patients with NAFLD in 
a placebo-controlled trial and their results showed no 
effect on serum levels of hepatic enzymes, HOMA-
IR, or on the degree of hepatic steatosis. However, 
their study did demonstrate the beneficial effects of 
vitamin D on serum malondialdehyde, a marker of lipid 
peroxidation, and on CRP levels. 
Studies with a longer intervention period are 
warranted in order to explore the effects of long term 
exposure to vitamin D on NAFLD and on the associated 
systemic inflammation it causes, as well as on the 
prevention of NAFLD.
CONCLUSION
There is a well-established inverse relationship 
between vitamin D status and obesity, and hypovita-
minosis D is associated with an unfavorable metabolic 
and inflammatory profile. Obesity-related systemic 
low grade inflammation characterized by alterations 
in levels of circulating adipokines is suggested to 
be involved in the pathogenesis of NAFLD and in its 
progression to NASH. Vitamin D deficiency is also 
associated with NAFLD and has even been correlated 
with the severity of the disease. Recent data has 
suggested that vitamin D’s anti-inflammatory and 
immune-modulatory properties provide plausible 
mechanisms by which hypovitaminosis D may link 
adipose tissue dysfunction to the various steps in the 
progression of NAFLD. Several animal studies have 
added further weight to this hypothesis by showing 
the beneficial effect of vitamin D supplementation 
on  systemic  inflammation  and  on  NAFLD  in  a  murine  
model, although these data are not yet confirmed 
by the results of the clinical trials conducted to date 
in humans. Further specifically-designed long-term 
randomized placebo-controlled trials are needed to clarify 
the therapeutic impact of vitamin D supplementation in 
NAFLD.
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